Add to ORKGKRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emerging evidence from mouse models of lung cancer suggests that ERBB RTKs may amplify signalling through RAS isoforms and participate in mutant RAS-driven lung cancer. This is one of 3 datasets where we examined the transcriptional impact of treatment of KRAS mutant human lung cancer cell lines with the multi-ERBB inhibitor Neratini
Most non-small cell lung cancers (NSCLC) contain nontargetable mutations, including KRAS, TP53, or S...
KRAS-activation mutations occur in 25% to 40% of lung adenocarcinomas and are a known mechanism of e...
Purpose: Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some age...
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emergi...
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emergi...
Lung cancer is the leading cause of cancer deaths. Tumor heterogeneity, which hampers development of...
SummaryKRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available ...
On the basis of clinical trials using first-generation epidermal growth factor receptor (EGFR) tyros...
ABSTRACT Using a panel of non–small cell lung cancer (NSCLC) lines, we show here that MAP-ERK kinase...
Lung cancer is currently the most deadly malignancy in industrialized countries and accounts for 18%...
Lung cancer is currently the most deadly malignancy in industrialized countries and accounts for 18 ...
SummaryThere are no effective therapies for the ∼30% of human malignancies with mutant RAS oncogenes...
[[abstract]]Evaluation of: Zhou Y, Rideout WM 3rd, Zi T et al.: Chimeric mouse tumor models reveal d...
There are no effective therapies for the ∼30% of human malignancies with mutant RAS oncogenes. Using...
The 5-year survival rate of lung cancer patients is only 16%. As most patients are diagnosed at an a...
Most non-small cell lung cancers (NSCLC) contain nontargetable mutations, including KRAS, TP53, or S...
KRAS-activation mutations occur in 25% to 40% of lung adenocarcinomas and are a known mechanism of e...
Purpose: Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some age...
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emergi...
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emergi...
Lung cancer is the leading cause of cancer deaths. Tumor heterogeneity, which hampers development of...
SummaryKRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available ...
On the basis of clinical trials using first-generation epidermal growth factor receptor (EGFR) tyros...
ABSTRACT Using a panel of non–small cell lung cancer (NSCLC) lines, we show here that MAP-ERK kinase...
Lung cancer is currently the most deadly malignancy in industrialized countries and accounts for 18%...
Lung cancer is currently the most deadly malignancy in industrialized countries and accounts for 18 ...
SummaryThere are no effective therapies for the ∼30% of human malignancies with mutant RAS oncogenes...
[[abstract]]Evaluation of: Zhou Y, Rideout WM 3rd, Zi T et al.: Chimeric mouse tumor models reveal d...
There are no effective therapies for the ∼30% of human malignancies with mutant RAS oncogenes. Using...
The 5-year survival rate of lung cancer patients is only 16%. As most patients are diagnosed at an a...
Most non-small cell lung cancers (NSCLC) contain nontargetable mutations, including KRAS, TP53, or S...
KRAS-activation mutations occur in 25% to 40% of lung adenocarcinomas and are a known mechanism of e...
Purpose: Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some age...